Welcome to our dedicated page for Stoke Therapeutics news (Ticker: STOK), a resource for investors and traders seeking the latest updates and insights on Stoke Therapeutics stock.
Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company that develops RNA-based medicines to restore protein expression in severe genetic diseases. Its news flow is closely tied to the progress of its antisense oligonucleotide programs, particularly zorevunersen for Dravet syndrome and STK-002 for Autosomal Dominant Optic Atrophy (ADOA).
Investors following STOK news can expect regular updates on clinical development milestones. These include announcements on the global Phase 3 EMPEROR study of zorevunersen in children and adolescents with Dravet syndrome, multi-year data from open-label extension studies, and analyses comparing treated patients with natural history data. Stoke also reports on natural history research such as the FALCON study in ADOA, which informs the design of interventional trials like the OSPREY Phase 1 study of STK-002.
Regulatory and collaboration developments are another important category of news. Stoke highlights regulatory designations for zorevunersen, including orphan drug, rare pediatric disease, and Breakthrough Therapy Designation, as well as its strategic collaboration with Biogen, under which the companies jointly advance zorevunersen for Dravet syndrome with defined regional commercialization rights.
Corporate and financial updates appear in press releases and are often paired with SEC filings. These items cover quarterly financial results, cash runway commentary, stock-based inducement grants under Nasdaq Listing Rule 5635(c)(4), and participation in major healthcare and investor conferences. Webcasts and conference calls for analysts and investors are also announced through news releases.
For anyone researching STOK, the news stream provides context on how Stoke Therapeutics is advancing its TANGO antisense platform, executing clinical trials in rare neurological and ophthalmic diseases, and managing its partnerships and capital to support ongoing development.
Stoke Therapeutics (NASDAQ: STOK) announced that five abstracts regarding STK-001 for treating Dravet syndrome will be presented at the American Epilepsy Society annual meeting from December 3-7, 2021 in Chicago. The presentations include interim data on safety, pharmacokinetics, and exposure from the Phase 1/2a MONARCH study. Stoke aims to develop the first disease-modifying therapy for Dravet syndrome, a severe genetic epilepsy with no approved therapies. Updates from the ongoing studies will provide insights into treatment efficacy and safety.
Stoke Therapeutics, Inc. (Nasdaq: STOK) has nominated STK-002 as a clinical candidate targeting autosomal dominant optic atrophy (ADOA), an inherited optic nerve disorder. The company reported financial results for Q3 2021, showing a net loss of $22.6 million, or $0.61 per share, compared to $13.7 million, or $0.41 per share in 2020. Research and development expenses rose to $14.4 million from $8.1 million year-over-year. With $236.9 million in cash as of September 30, 2021, Stoke expects to fund operations through 2023. Positive interim data from the MONARCH study of STK-001 was also highlighted.
Stoke Therapeutics, Inc. (NASDAQ: STOK), a biotechnology firm focused on RNA-based therapies, has announced participation in two investor conferences this November. The Credit Suisse 30th Annual Healthcare Conference will take place on November 10, 2021, at 10:30 a.m. ET, followed by the Stifel 2021 Virtual Healthcare Conference on November 15, 2021, at 3:20 p.m. ET. Live webcasts of the presentations will be available on Stoke's website, with replays accessible for 30 days afterwards. Stoke is advancing therapies for severe diseases via its proprietary TANGO approach.
Stoke Therapeutics (Nasdaq: STOK) is set to present at the Cantor Global Healthcare Virtual Conference on September 28, 2021, at 4:00 p.m. ET. Chief Medical Officer Barry Ticho, M.D., Ph.D., will lead the session in a fireside chat format, which will be accessible via live audio webcast on the company's website. Stoke is a biotechnology firm focused on RNA-based medicines to treat severe diseases caused by protein expression deficiencies, including its lead candidate, STK-001, for Dravet syndrome and potential therapies for autosomal dominant optic atrophy.
Stoke Therapeutics announced positive interim results for STK-001, an investigational medicine for treating Dravet syndrome. The Phase 1/2a MONARCH study indicated that single doses up to 30mg were well-tolerated, showing no safety concerns. A trend toward reduced convulsive seizures was noted, especially in younger patients. Over 95% of subjects could achieve pharmacologically active levels with three doses of 30mg. The FDA has allowed the evaluation of a higher 45mg dose in the study. Ongoing studies aim to establish effective dosing and long-term treatment strategies.
Stoke Therapeutics, Inc. (Nasdaq: STOK) announced its Q2 2021 financial results, reporting a net loss of $22.0 million or $0.60 per share, up from $13.0 million or $0.39 per share in Q2 2020. Research and development expenses increased to $14.1 million from $8.0 million. The company completed dosing in the MONARCH study of STK-001 for Dravet syndrome and expects interim analysis results in Q3 2021. Stoke plans to identify a clinical candidate for autosomal dominant optic atrophy (ADOA) by year-end 2021, and as of June 30, 2021, had around $251.4 million available to fund operations into 2024.
Stoke Therapeutics (Nasdaq: STOK), a biotechnology company focused on RNA-based medicines, will have CEO Edward M. Kaye present at the UBS Global Healthcare Virtual Conference on May 24, 2021, at 5:00 p.m. ET. The presentation will be in a fireside chat format and will be available through a live audio webcast on Stoke's website. A replay will be accessible for 30 days. Stoke is known for its innovative TANGO approach, working on antisense oligonucleotides (ASOs) to treat severe diseases like Dravet syndrome and autosomal dominant optic atrophy.
Stoke Therapeutics (Nasdaq: STOK) reported a net loss of $16.8 million for Q1 2021, increasing from $11 million a year prior. R&D expenses rose to $9.9 million, and general administrative costs reached $6.9 million. The company is advancing its pipeline with full enrollment of the Phase 1/2a MONARCH study for STK-001 in Dravet syndrome. Key upcoming milestones include preliminary data from MONARCH expected in Q3 2021 and initiation of the ADMIRAL study in the UK. Stoke holds approximately $267.7 million in cash to fund operations through 2024.
Stoke Therapeutics (Nasdaq: STOK) announced new preclinical data showing successful in-vitro protein upregulation and enhanced mitochondrial function in fibroblasts from ADOA patients. This data highlights the effectiveness of their TANGO approach in addressing the OPA1 protein deficiency, the primary cause of ADOA. With ADOA affecting approximately 1 in 30,000 people, the findings suggest a path toward disease-modifying treatment. Key results include a 35% to 47% increase in OPA1 protein isoform expression and improved mitochondrial bioenergetics.
Stoke Therapeutics (Nasdaq: STOK) announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has authorized its Clinical Trial Application for a Phase 1/2a study (ADMIRAL) of STK-001, targeting Dravet syndrome. This proprietary antisense oligonucleotide aims to be the first disease-modifying therapy for this genetic epilepsy, which involves severe seizures and cognitive deficits. The study plans to enroll 22 patients across UK sites, with patient enrollment expected in the second half of 2021. STK-001 is currently in another trial (MONARCH) in the U.S., where initial dose cohorts are underway.